These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 20520852)
1. The antipsychotic potential of muscarinic allosteric modulation. Bridges TM; LeBois EP; Hopkins CR; Wood MR; Jones CK; Conn PJ; Lindsley CW Drug News Perspect; 2010 May; 23(4):229-40. PubMed ID: 20520852 [TBL] [Abstract][Full Text] [Related]
2. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. Mirza NR; Peters D; Sparks RG CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557 [TBL] [Abstract][Full Text] [Related]
3. Classics in Chemical Neuroscience: Xanomeline. Bender AM; Jones CK; Lindsley CW ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924 [TBL] [Abstract][Full Text] [Related]
4. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348 [TBL] [Abstract][Full Text] [Related]
13. Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor. Jakubík J; Tucek S; El-Fakahany EE J Pharmacol Exp Ther; 2002 Jun; 301(3):1033-41. PubMed ID: 12023535 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575 [TBL] [Abstract][Full Text] [Related]
15. Discovery and Development of Muscarinic Acetylcholine M Takai K; Enomoto T Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510 [TBL] [Abstract][Full Text] [Related]
16. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. Li Z; Snigdha S; Roseman AS; Dai J; Meltzer HY Eur J Pharmacol; 2008 Oct; 596(1-3):89-97. PubMed ID: 18771666 [TBL] [Abstract][Full Text] [Related]
17. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Barak S; Weiner I Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109 [TBL] [Abstract][Full Text] [Related]
18. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. Nawaratne V; Leach K; Felder CC; Sexton PM; Christopoulos A J Biol Chem; 2010 Jun; 285(25):19012-21. PubMed ID: 20406819 [TBL] [Abstract][Full Text] [Related]
19. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Davies MA; Compton-Toth BA; Hufeisen SJ; Meltzer HY; Roth BL Psychopharmacology (Berl); 2005 Apr; 178(4):451-60. PubMed ID: 15765260 [TBL] [Abstract][Full Text] [Related]
20. Tacrine-xanomeline and tacrine-iperoxo hybrid ligands: Synthesis and biological evaluation at acetylcholinesterase and M Maspero M; Volpato D; Cirillo D; Yuan Chen N; Messerer R; Sotriffer C; De Amici M; Holzgrabe U; Dallanoce C Bioorg Chem; 2020 Mar; 96():103633. PubMed ID: 32032848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]